Skip to main content
Journal cover image

FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?

Publication ,  Journal Article
Jafar, TH
Published in: Lancet (London, England)
July 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet (London, England)

DOI

EISSN

1474-547X

ISSN

0140-6736

Publication Date

July 2021

Volume

398

Issue

10297

Start / End Page

283 / 284

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Sodium-Glucose Transporter 2 Inhibitors
  • Renal Insufficiency, Chronic
  • Humans
  • Glucosides
  • General & Internal Medicine
  • Drug Approval
  • Benzhydryl Compounds
  • 42 Health sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jafar, T. H. (2021). FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Lancet (London, England), 398(10297), 283–284. https://doi.org/10.1016/s0140-6736(21)01242-3
Jafar, Tazeen H. “FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?Lancet (London, England) 398, no. 10297 (July 2021): 283–84. https://doi.org/10.1016/s0140-6736(21)01242-3.
Jafar TH. FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Lancet (London, England). 2021 Jul;398(10297):283–4.
Jafar, Tazeen H. “FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?Lancet (London, England), vol. 398, no. 10297, July 2021, pp. 283–84. Epmc, doi:10.1016/s0140-6736(21)01242-3.
Jafar TH. FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Lancet (London, England). 2021 Jul;398(10297):283–284.
Journal cover image

Published In

Lancet (London, England)

DOI

EISSN

1474-547X

ISSN

0140-6736

Publication Date

July 2021

Volume

398

Issue

10297

Start / End Page

283 / 284

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Sodium-Glucose Transporter 2 Inhibitors
  • Renal Insufficiency, Chronic
  • Humans
  • Glucosides
  • General & Internal Medicine
  • Drug Approval
  • Benzhydryl Compounds
  • 42 Health sciences